Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes

Neurotoxicology and Teratology

Volumn 24, Issue 5, 2002, Pages 675-682

  Maruyama, Wakako ^a   Akao, Yukihiro ^b   Carrillo, Maria Chrisina ^c   Kitani, Ken Ichi ^a   Youdium, Moussa B H ^d   Naoi, Makoto ^e  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e Institute of Physical and Chemical Research   (Japan)

Author keywords

Apoptosis; Dopamine neuron; Mitochondrial permeability transition; N methyl(R)salsolinol; Parkinson's disease; Rasagiline

Indexed keywords

ALIPHATIC AMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATALASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROPROTECTIVE AGENT; PROPARGYLAMINE; PROTEIN BCL 2; RASAGILINE; SALSOLINOL; SELEGILINE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN REGION; CELL DEATH; CELL LINE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GENE INDUCTION; HUMAN; HUMAN CELL; MALE; MEMBRANE PERMEABILITY; MITOCHONDRION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL SURVIVAL; DOPAMINE; GENE EXPRESSION; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PARGYLINE; PARKINSON DISEASE; PROPYLAMINES; SUBSTANTIA NIGRA;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 0036719861     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(02)00221-0     Document Type: Review

References (60)

1. Apoptosis induced by endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3
2. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
3. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
4. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase
5. Effect of ethylcholine mustard aziridinium (AF64A) and of the monoamine oxidase-B-inhibitor L-deprenyl on the morphology of the rat hippocampus
6. (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: The sex and age-related differences in the optimal dose in the rat
7. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat
8. An evaluation of the role of mitochondria in neurodegenerative diseases: Mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration
9. L-Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
10. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites
11. Tyramine antagonistic properties of AGN-1135 - An irreversible inhibitor of monoamine oxidase type B
12. Pharmacology and neuroprotective properties of rasagiline
13. Increased survival of dopamine neurons by rasagiline, a monoamine oxidase B inhibitor
14. Inhibition of interleukin 1b converting enzyme family proteases reduced ischemic and excitotoxic neuronal damage
15. Caspase 3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
16. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors
17. Neuroprotective effect of rasagiline, a selective monoamine oxidase B inhibitor, against closed head injury in the mouse
18. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons
19. Cell death mechanism in Parkinson's disease
20. ONO-1603, a potential antidementia drug, delays age-induced apoptosis and suppresses overexpression of glyceraldehydes-3-phosphate dehydrogenase in cultured central nervous system neurons
21. Efficiency and safety of rasagiline as monotherapy in the early Parkinson's disease. Abstract of the XIV International Congress on Parkinson's disease
22. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenypyridinium
23. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
24. The mitochondrial death/life regulation in apoptosis and necrosis
25. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo
26. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update
27. An endogenous dopaminergic neurotoxin, N-methyl(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells
28. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide
29. Neuroprotection by (-)-deprenyl and related compounds
30. Neurotoxins induce apoptosis in dopamine neurons: Protection by N-propargyl-1(R)- and (S)-aminoindan, rasagiline and TV 1022
31. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: Suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine
32. Transfection-enforced Bcl-2 overexpression and an antiparkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehydes-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol
33. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells
34. Superoxide dismutase. An enzymatic function for erythrocuprein (hemocuprein)
35. Caspase activities and tumor necrosis factor receptor R1 (p55) are elevated in the substantia nigra from parkinsonian brain
36. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion
37. Oxidation of N-methyl (R)salsolinol: Involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines
38. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)Salsolinol, in dopamine neurons
39. Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: Induction of apoptosis and protection by (-)deprenyl
40. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria
41. Effect of deprenyl on the progression of disability in early Parkinson's disease
42. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
43. The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition
44. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
45. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage
46. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC
47. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavioral in the postnatal anoxia rat
48. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease
49. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis
50. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration
51. Apoptosis in the pathogenesis and treatment of disease
52. Bcl-2 family: Life-death switch
53. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl
54. Neurorescuing effects of the GAPDH ligand CGP 3466B
55. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo
56. Aliphatic propargylamines: Potent, selective, irreversible monoamine oxidase B inhibitors
57. Neurochemical and neuroprotective effects of some aliphatic propargylamines: New selective nonamphetamine-like monoamine oxidase B inhibitors
58. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis
59. Neuroprotection by R(-)-deprenyl and N-2-hexyl-N-methylpropargylamine on DSP-4, a neurotoxin, induced degeneration of noradrenergic neurons in the rat locus coeruleus